Inovio Pharmaceuticals (INO) Long-Term Investments (2010 - 2025)

Inovio Pharmaceuticals has reported Long-Term Investments for 16 years, with the latest figure at $2.1 million in Q4 2025.

• Quarterly Long-Term Investments rose 30.35% year-over-year to $2.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.1 million (up 30.35% YoY) and the FY2025 annual result came in at $2.1 million, up 30.35% from the prior year.
• Long-Term Investments fell to $2.1 million in Q4 2025 per INO's latest filing, from $2.5 million in the prior quarter.
• Over five years, Long-Term Investments peaked at $3.9 million in Q4 2021 and troughed at $1.6 million in Q4 2024.
• A 5-year average of $2.7 million and a median of $2.6 million in 2023 frame the typical range for Long-Term Investments.
• The sharpest annual moves came in 2021 and 2022: Long-Term Investments surged 305.89% in 2021, then slumped 48.62% in 2022.
• Over 5 years, Long-Term Investments stood at $3.9 million in 2021, then plunged by 48.62% to $2.0 million in 2022, then soared by 38.52% to $2.8 million in 2023, then sank by 41.95% to $1.6 million in 2024, then soared by 30.35% to $2.1 million in 2025.
• According to Business Quant data, Long-Term Investments over the past three periods registered $2.1 million, $2.5 million, and $3.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.